Financial Performance - The company reported an impressive operating cash flow of 0.92 CNY per share, reflecting a year-on-year increase of 991.52% [2] - The net cash flow from operating activities increased by 993.71% due to optimized cash flow management and accelerated discounting of receivables [2][5] Sales and Marketing Strategy - The company has established a strong presence in both B2C and O2O channels, achieving rapid growth by collaborating with major platforms and expanding its online medical resources [3] - The O2O strategy focuses on differentiated operations based on consumer needs, enhancing exposure and conversion rates through targeted marketing [3] - The company’s pain relief patches have outperformed the industry growth rate due to their dual efficacy in pain relief and anti-inflammation [4] Research and Development - The company is concentrating its R&D efforts on key therapeutic areas such as external pain relief, respiratory, and neurological treatments, with a focus on unmet clinical needs [4][6] - The new drug "Xiaoer Relixin Granules" has received clinical trial approval, enhancing the pediatric product pipeline [5] - R&D investment reached 48.65 million CNY in the first half of the year, a 3.31% increase year-on-year, with a R&D expense ratio of 5.6%, below the industry average [6] Market Position and Competitive Advantage - The company has established itself as a leading brand in the Tibetan medicine market, particularly in external pain relief [6] - The competitive landscape has intensified due to increased demand for topical anti-inflammatory products, but the company maintains a unique advantage with its multi-target Tibetan medicine formulations [4] - The company’s strategic focus on brand recognition and product differentiation supports its market leadership [6] Future Outlook - The company plans to enhance its cash flow management through improved receivables management and expanded financing channels to support business growth and R&D investments [5] - The ongoing construction of the pharmaceutical industrial base is on track, with production licenses being obtained for various formulations [4]

Core Viewpoint - Qizheng Tibetan Medicine has not yet obtained the official "Project Medical Guarantee Procurement List" and is preparing to address diverse health needs in the Tibetan region, including both short-term and long-term health management risks [2] Group 1: Short-term Health Management - The company has prepared Red Jingtian Oral Liquid for managing acute altitude sickness and Xin Xin for addressing weakness [2] Group 2: Long-term Health Management - For long-term health risks, the company has secured 21 Tibetan medicine approvals for digestive metabolism issues and 11 for cardiovascular problems [2] - The company has also prepared 19 Tibetan medicine approvals for musculoskeletal diseases, including leading products like Qizheng Pain Relief Plaster, which utilizes unique wet application technology for better penetration and clinical efficacy [2] Group 3: Market Strategy - The company aims to ensure supply and meet market demand while focusing on brand development [2]